Impact of Liraglutide 3.0 on Body Fat Distribution

NCT03038620 on ClinicalTrials.gov · last registry update 2021-11-19

An unusually large phase 4: 235 participants, more than double the 75 typical for the stage. The sponsor logged completion for 13 October 2020. Primary outcome, as filed: Relative Percent Reduction in Visceral Adipose Tissue Mass Measured by MRI. liraglutide is already approved in the US for cardiovascular disease and obesity, so this is asking a further question rather than establishing the drug works at all.

Status: COMPLETED
Phase: P4
Drug: liraglutide
Saxenda, Victoza, Xultophy
Sponsor: University of Texas Southwestern Medical Center
Sponsor type: Other
Enrollment: 235
Started: 2017-01
Primary completion: 2020-10-13 actual

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Relative Percent Reduction in Visceral Adipose Tissue Mass Measured by MRI

Conditions studied

Obesity, Visceral · Cardiovascular Diseases · Fat Disorder

Every field above is taken directly from the registry record. See all detected changes across the class, or the liraglutide page for this molecule’s full trial and approval history.